Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder

Seth D. Friedman; Stephen R. Dager; Aimee Parow; Fuyuki Hirashima; Christina Demopulos; Andrew L. Stoll; In Kyoon Lyoo; David L. Dunner; Perry F. Renshaw

doi:10.1016/j.biopsych.2004.06.012

Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder

Seth D. Friedman, Stephen R. Dager, Aimee Parow, Fuyuki Hirashima, Christina Demopulos, Andrew L. Stoll, In Kyoon Lyoo, David L. Dunner, Perry F. Renshaw

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

128 Scopus citations

Abstract

Background: Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC). This study examined whether lithium (Li) and valproic acid (VPA) treatment modulated these chemicals. Methods: A subset of previously reported BP patients were treated with Li (n = 12, 3.6 ± 1.9 months) or VPA (n = 9, 1.4 ± 1.7 months) and compared untreated HC subjects (n = 12, 2.9 ± 2.4 months) using proton echo-planar spectroscopic imaging. Regression analyses (voxel gray/white composition by chemistry) were performed at each time point, and change scores computed. Metabolite relaxation and regions of interest (ROI) were also examined. Results: Across treatment, Li-treated BP subjects demonstrated GM Glx decreases (Li-HC, p =. 08; Li-VPA p =. 04) and GM myo-inositol increases (Li-HC p =. 07; Li-VPA p =. 12). Other measures were not significant. Serum Li levels were positively correlated with Glx decreases at the trend level. Conclusions: Li treatment of BP was associated with specific GM Glx decreases and myo-inositol increases. Findings are discussed in the context of cellular mechanisms postulated to underlie Li and VPA therapeutic efficacy.

Original language	English
Pages (from-to)	340-348
Number of pages	9
Journal	Biological Psychiatry
Volume	56
Issue number	5
DOIs	https://doi.org/10.1016/j.biopsych.2004.06.012
State	Published - 1 Sep 2004

Bibliographical note

Funding Information:
This study was supported in part by Grant No. RO1 MH58681 from the National Institute of Mental Health, Bethesda, Maryland, and the Poitras Foundation and the Stanley Foundation Bipolar Disorders Research Center at McLean Hospital, Boston, Massachusetts. Jeffrey Munson, Ph.D. provided helpful discussions on statistical handling for this manuscript.

Keywords

Bipolar disorder
glutamate
glutamine
lithium
spectroscopy
valproic acid

Access to Document

10.1016/j.biopsych.2004.06.012

Cite this

@article{633d30baefd24d7f9d5ecb0f7bc40e96,

title = "Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder",

abstract = "Background: Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC). This study examined whether lithium (Li) and valproic acid (VPA) treatment modulated these chemicals. Methods: A subset of previously reported BP patients were treated with Li (n = 12, 3.6 ± 1.9 months) or VPA (n = 9, 1.4 ± 1.7 months) and compared untreated HC subjects (n = 12, 2.9 ± 2.4 months) using proton echo-planar spectroscopic imaging. Regression analyses (voxel gray/white composition by chemistry) were performed at each time point, and change scores computed. Metabolite relaxation and regions of interest (ROI) were also examined. Results: Across treatment, Li-treated BP subjects demonstrated GM Glx decreases (Li-HC, p =. 08; Li-VPA p =. 04) and GM myo-inositol increases (Li-HC p =. 07; Li-VPA p =. 12). Other measures were not significant. Serum Li levels were positively correlated with Glx decreases at the trend level. Conclusions: Li treatment of BP was associated with specific GM Glx decreases and myo-inositol increases. Findings are discussed in the context of cellular mechanisms postulated to underlie Li and VPA therapeutic efficacy.",

keywords = "Bipolar disorder, glutamate, glutamine, lithium, spectroscopy, valproic acid",

author = "Friedman, {Seth D.} and Dager, {Stephen R.} and Aimee Parow and Fuyuki Hirashima and Christina Demopulos and Stoll, {Andrew L.} and Lyoo, {In Kyoon} and Dunner, {David L.} and Renshaw, {Perry F.}",

note = "Funding Information: This study was supported in part by Grant No. RO1 MH58681 from the National Institute of Mental Health, Bethesda, Maryland, and the Poitras Foundation and the Stanley Foundation Bipolar Disorders Research Center at McLean Hospital, Boston, Massachusetts. Jeffrey Munson, Ph.D. provided helpful discussions on statistical handling for this manuscript.",

year = "2004",

month = sep,

day = "1",

doi = "10.1016/j.biopsych.2004.06.012",

language = "English",

volume = "56",

pages = "340--348",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder

AU - Friedman, Seth D.

AU - Dager, Stephen R.

AU - Parow, Aimee

AU - Hirashima, Fuyuki

AU - Demopulos, Christina

AU - Stoll, Andrew L.

AU - Lyoo, In Kyoon

AU - Dunner, David L.

AU - Renshaw, Perry F.

N1 - Funding Information: This study was supported in part by Grant No. RO1 MH58681 from the National Institute of Mental Health, Bethesda, Maryland, and the Poitras Foundation and the Stanley Foundation Bipolar Disorders Research Center at McLean Hospital, Boston, Massachusetts. Jeffrey Munson, Ph.D. provided helpful discussions on statistical handling for this manuscript.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background: Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC). This study examined whether lithium (Li) and valproic acid (VPA) treatment modulated these chemicals. Methods: A subset of previously reported BP patients were treated with Li (n = 12, 3.6 ± 1.9 months) or VPA (n = 9, 1.4 ± 1.7 months) and compared untreated HC subjects (n = 12, 2.9 ± 2.4 months) using proton echo-planar spectroscopic imaging. Regression analyses (voxel gray/white composition by chemistry) were performed at each time point, and change scores computed. Metabolite relaxation and regions of interest (ROI) were also examined. Results: Across treatment, Li-treated BP subjects demonstrated GM Glx decreases (Li-HC, p =. 08; Li-VPA p =. 04) and GM myo-inositol increases (Li-HC p =. 07; Li-VPA p =. 12). Other measures were not significant. Serum Li levels were positively correlated with Glx decreases at the trend level. Conclusions: Li treatment of BP was associated with specific GM Glx decreases and myo-inositol increases. Findings are discussed in the context of cellular mechanisms postulated to underlie Li and VPA therapeutic efficacy.

AB - Background: Prior work reported elevated gray matter (GM) lactate and Glx (glutamate + glutamine + GABA) concentrations in unmedicated patients with bipolar disorder (BP) compared with healthy controls (HC). This study examined whether lithium (Li) and valproic acid (VPA) treatment modulated these chemicals. Methods: A subset of previously reported BP patients were treated with Li (n = 12, 3.6 ± 1.9 months) or VPA (n = 9, 1.4 ± 1.7 months) and compared untreated HC subjects (n = 12, 2.9 ± 2.4 months) using proton echo-planar spectroscopic imaging. Regression analyses (voxel gray/white composition by chemistry) were performed at each time point, and change scores computed. Metabolite relaxation and regions of interest (ROI) were also examined. Results: Across treatment, Li-treated BP subjects demonstrated GM Glx decreases (Li-HC, p =. 08; Li-VPA p =. 04) and GM myo-inositol increases (Li-HC p =. 07; Li-VPA p =. 12). Other measures were not significant. Serum Li levels were positively correlated with Glx decreases at the trend level. Conclusions: Li treatment of BP was associated with specific GM Glx decreases and myo-inositol increases. Findings are discussed in the context of cellular mechanisms postulated to underlie Li and VPA therapeutic efficacy.

KW - Bipolar disorder

KW - glutamate

KW - glutamine

KW - lithium

KW - spectroscopy

KW - valproic acid

UR - http://www.scopus.com/inward/record.url?scp=4444380612&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2004.06.012

DO - 10.1016/j.biopsych.2004.06.012

M3 - Article

C2 - 15336516

AN - SCOPUS:4444380612

SN - 0006-3223

VL - 56

SP - 340

EP - 348

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 5

ER -

Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this